Nedocromil (Tilade) and sodium cromoglicate (Intal Forte) inhaler: Discontinuation

Discontinuation Active

Tilade and Intal Forte inhalers are mast cell stabilisers primarily used for the preventative treatment of asthma. 

On this page

Tilade and Intal Forte inhalers discontinued

Sanofi, the supplier of nedocromil and sodium cromoglicate inhalers, is discontinuing its Tilade and Intal Forte inhalers in New Zealand.

Nedocromil and sodium cromoglicate inhalers will no longer be available once the current supply runs out.

  • Supply of Tilade inhalers is likely to run out by late November 2020.
  • Supply of Intal Forte inhalers is likely to run out by March 2021.

Information for patients

You will need to talk to your prescriber about other medicines to help you control your asthma.

There are no other funded nedocromil or sodium cromoglicate inhalers. However there are a number of other funded preventer inhalers you could switch to. Your prescriber can advise you on what treatments will work best for you. 

We know that changing medications can be a hassle and we're sorry for any inconvenience this causes.

Read more about managing asthma – Health Navigator website(external link)

Information for prescribers

You will need to: 

  • ensure no new patients are started on Tilade or Intal Forte inhalers
  • transition patients currently on Tilade or Intal Forte inhalers to alternative treatments.

From 1 July 2020, sodium cromoglicate and nedocromil inhalers were no longer funded for new patients.

We have received advice from the Respiratory Subcommittee of the Pharmacology and Therapeutics Advisory Committee (one of our expert clinical advisory groups). They advise that patients can be managed on alternative treatments, in line with current asthma guidelines. These treatments include:

  • inhaled corticosteroids
  • inhaled corticosteroid and long-acting beta-adrenoceptor agonist combinations
  • montelukast
  • P.R.N short-acting beta-adrenoceptor agonists.

Check the full list of funded treatments in the Pharmaceutical Schedule(external link)

This information is for health professionals and summarises the clinical advice we received on possible alternatives to Tilade and Intal Forte inhalers.

PHARMAC cannot give clinical advice to individuals. This information is a guide only.

More information

The Asthma and Respiratory Foundation NZ Adult Asthma Guidelines are a useful tool for health professionals to use when reviewing an individual’s asthma care.

Download the guidelines for adults – NZ Respiratory Guidelines website(external link)

BPACnz has published information on managing adults with asthma in primary care which may be useful.

Read Managing Adults with Asthma in Primary Care: The Four-Stage Consultation – BPACnz's website(external link) 

Information for pharmacists 

Stock of the:

  • Tilade inhaler is expected to be exhausted by late November 2020.
  • Intal Forte inhaler is expected to be exhausted by March 2021. 

There are no other funded nedocromil or sodium cromoglicate inhalers.

Subsidy for existing patients only from 1 July 2020

Since 1 July 2020, sodium cromoglicate and nedocromil is only subsidised for patients who were taking that medicine before 1 July 2020.

Pharmacists will need to annotate the prescription as endorsed where a record of prior dispensing exists.  

Delisting from the Pharmaceutical Schedule 

Tilade will be delisted from 1 February 2021

Intal Forte will be delisted from 1 May 2021.